C4 Therapeutics, INC 10-Q quarterly reports

C4 Therapeutics has entered into a significant research collaboration and license agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to develop degrader-antibody conjugates (DACs).

C4 Therapeutics, Inc. filed its Form 10-Q for the quarter ended March 31, 2026, detailing its financial performance, ongoing clinical trials, and strategic collaborations.

C4 Therapeutics reported increased Q3 2025 net losses but bolstered its cash position with a $117 million underwritten offering, extending its operational runway to the end of 2028.

C4 Therapeutics reported increased net losses in Q2 2025, driven by higher research and development expenses, while maintaining a cash runway into mid-2027.

C4 Therapeutics' Q1 2025 results show increased collaboration revenue and ongoing clinical development, but significant operating losses persist.

C4 Therapeutics reports a net loss of $70.7 million for the nine months ended September 30, 2024, while highlighting progress in clinical trials and collaborations.

C4 Therapeutics reports a net loss of $46.1 million for the first half of 2024, with collaboration revenue increasing significantly compared to the same period last year.

C4 Therapeutics reports a net loss of $28.4 million for the first quarter of 2024, alongside strategic decisions impacting their clinical programs and collaborations.